Navigation Links
NOVAVAX to Present at the Influenza Congress USA 2009
Date:11/11/2009

ROCKVILLE, Md., Nov. 11 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that John Trizzino, Senior Vice President, International and Government Alliances, will be presenting at the Influenza Congress USA 2009. Mr. Trizzino's presentation will take place at 3:30 pm local time on November 20, 2009 at The Westin Washington, Washington D.C. Mr. Trizzino will be discussing regional partnership drivers, benefits of regional partnerships and value-creation through regional partnerships in a Case Study titled: Regional partners as a unique commercialization strategy.

About the Influenza Congress USA 2009

Influenza Congress USA is an annual influenza conference in North America addressing every aspect of influenza policy and planning, influenza research, development and stakeholder partnerships. The influenza vaccine is the fastest growing segment in the adult vaccine market and the United States accounts for over 50% of the global vaccine market. Annually, more than 3.5 million people die of influenza. By 2016, this market is expected to grow to $4.4 billion. H1N1 remains the most immediate threat.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP -based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The Company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com

SOURCE Novavax, Inc.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Beacon Equity Researches: Sanofi-Aventis, Amazon, Yahoo, Johnson & Johnson, Novavax and NexMed
2. Novavax Announces Closing of $11 Million Common Stock Sale to Subsidiary of Cadila Pharmaceuticals
3. Novavax Reports Fourth Quarter and 2008 Year-End Financial Results
4. Novavax Announces Release Date of 2007 Fourth Quarter, Full Year Financial Results and Investor Conference Call
5. Novavax CEO to Present at the Partnering for Global Health Forum
6. Novavax CEO to Present at Susquehannas Second SIGnificant Options in Healthcare Conference
7. Novavax Announces Release Date of 2007 Third Quarter Financial Results and Investor Conference Call
8. Novavax and Allergan Terminate Manufacturing Supply Agreement for Estrasorb
9. Novavax CEO to Present at the 2007 UBS Global Life Sciences Conference
10. American Academy of Physician Assistants Applauds U.S. House of Representatives for Passing Health Care Reform Bill
11. Tyco International to Present at the Citi Industrial Manufacturing & Transportation Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... Researchers can ... so routine. A fresh look at this technique may yield big benefits. Scientists ... reproducibility of experiments in a cell culture laboratory—and lessen the risk of contamination ...
(Date:5/23/2016)... ... May 23, 2016 , ... In light of ... reminds pet owners that intervening at the first sign of their pet overheating ... normal body mechanisms cannot keep the body’s temperature within a safe range. Considered ...
(Date:5/23/2016)... ... May 23, 2016 , ... The Society for Women’s Health ... to move on from that role. , “No one in Washington led the way ... said SWHR Founder Florence Haseltine, MD, PhD. “We offer our deep gratitude to Phyllis ...
(Date:5/23/2016)... ... 2016 , ... Hadley Institute for the Blind and Visually ... or visually impaired, announces the election of Julie S. Tye as its next ... of Trustees retained Morris & Berger, a firm specializing in non-profit executive searches, ...
(Date:5/23/2016)... NY (PRWEB) , ... May 23, 2016 , ... ... the company’s top management team to meet the needs of its recent and ... to drive continued growth and business development across widening market segments. Max joined ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... 23, 2016 Gamida Cell, a ... of cancer and orphan genetic diseases, announced today it ... million from the Israel Innovation Authority (formerly the Office ... Economy and Industry. The mission of the Israel Innovation ... industries, including science and technology, while stimulating economic growth. ...
(Date:5/22/2016)... 2016 DS Biopharma (DS) ... anti-inflammatory compound DS102 in chronic obstructive pulmonary disease ... (NASH) patients. Recent DS preclinical data ... tissue and has bronchodilatory, anti-inflammatory and anti-fibrotic properties ... Company will publish further detail on these findings ...
(Date:5/20/2016)... 2016 - Revenue Forecasts ... Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine ... New Study Reveals Selling Opportunities and Revenue Prospects ... ,What is the future of biologics, especially new ... commercial analysis. Staying ahead in data and knowledge, ...
Breaking Medicine Technology: